Are Māori women at increased risk of cardiac complications of Graves disease? by Nigam, Parul & Morton, Adam
THE NEW ZEALAND  
MEDICAL JOURNAL  
Journal of the New Zealand Medical Association 
 
NZMJ 20 January 2012, Vol 125 No 1348; ISSN 1175 8716 Page 90 
http://journal.nzma.org.nz/journal/125-1348/5023/ ©NZMA 
  
 
Are Māori women at increased risk of cardiac complications 
of Graves disease?  
Parul Nigam, Adam Morton 
Abstract 
We present a case series of three women of New Zealand Māori ethnicity, who 
presented to the emergency department of a Brisbane hospital (Brisbane, Australia) 
with symptomatic cardiac complications of Graves disease requiring hospital 
admission.  
We raise the question as to whether individuals of Māori ethnicity are genetically 
susceptible to cardiac complications of thyrotoxicosis. 
Case 1—A 35-year-old woman of New Zealand Māori ethnicity presented to the 
Emergency Department with palpitations, dyspnoea and muscle weakness. Graves 
disease had been diagnosed 4 years earlier but she had ceased carbimazole therapy 4 
months prior to presentation. The only other significant history was of mild episodic 
asthma. Her cardiovascular risk factors included a 10-pack year smoking history but 
no other history of hypertension, dyslipidaemia or any significant family history of 
cardiac disease.  
On clinical examination she was in atrial fibrillation (AF) with a ventricular rate of 
120 beats per minute (bpm), blood pressure (BP) was 120/80 mmHg, jugular venous 
pressure (JVP) was elevated 5 cm, heart sounds were dual with a clear chest. Thyroid 
was diffusely enlarged with a bruit on auscultation, and there was ophthalmopathy 
with tethering of the right medial rectus muscle. Free thyroxine (FT4) was more than 
77 pmol/L (normal 10–20 pmol/L), free triiodothyronine (FT3) was greater than 46 
pmol/L and thyroid stimulating hormone (TSH) was suppressed.  
Echocardiography revealed normal left ventricular size with global moderate systolic 
dysfunction (left ventricular ejection fraction 45%), moderately dilated right 
ventricular size with moderate dysfunction, moderate tricuspid regurgitation and 
moderate pulmonary hypertension with estimated right ventricular systolic pressure 
(RVSP) 60 mmHg. The woman was treated with prednisone 50 mg mane, 
carbimazole 60 mg per day, verapamil, digoxin and anticoagulation.  
One month later her FT4 was 17.1 pmol/L and FT3 was 7.6 pmol/L. Repeat 
echocardiography 6 weeks after initial presentation showed normal left ventricular 
function (ejection fraction 55–60%), normal right ventricular function and 
improvement in pulmonary hypertension with RVSP 38 mmHg. She reverted to sinus 
rhythm and proceeded to thyroidectomy. 
Case 2—A 75-year-old Māori woman presented to the Emergency Department 
because of palpitations, fatigue and heat intolerance. Her cardiac risk factors included 
a history of hypertension for the past 3 years and dyslipidaemia requiring medication. 
She was an ex-smoker.  
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On examination she was in AF with a ventricular rate of approximately 120 bpm, BP 
was 120/80 mmHg, JVP was elevated 4 cm with V waves, heart sounds were dual and 
chest was clear. There was a nodular goitre approximately 60 g in volume with no 
bruit and no ophthalmopathy. FT4 was 68.2 pmol/L, free T3 was 23.6 pmol/L and 
TSH was suppressed. Echocardiography revealed normal left ventricular size with 
globally impaired function with an estimated ejection fraction of 37%. There was 
mild right ventricular impairment, moderate to severe tricuspid regurgitation, and 
estimated RVSP was elevated at 45 mmHg. TSH receptor antibodies were elevated at 
25 consistent with Graves disease.  
She was treated with carbimazole 40 mg/day, prednisone 25 mg per day, propranolol 
80 mg per day and was also anticoagulated. Two weeks later her FT4 was 27 pmol/L 
and FT3 was 7.2 mol/L and she remained in atrial fibrillation. Repeat 
echocardiography 6 weeks after her initial presentation revealed improvement in left 
ventricular function (estimated LVEF 45–50%) and pulmonary hypertension (RVSP 
33 mmHg).  
Two months after her initial presentation it was noted she had reverted to sinus 
rhythm, and repeat echocardiography one year after presentation was completely 
normal. Her thyrotoxicosis remains in remission 12 months after cessation of drug 
therapy. 
Case 3—A 41-year-old woman of Māori ethnicity was brought to the Emergency 
Department having been noted to have tachycardia after a minor motor vehicle 
accident. Thyrotoxicosis due to Graves disease had been diagnosed 9 months earlier; 
however she had ceased thionamide medication 3 months prior to presentation. She 
had a 10-pack-year smoking history but no other significant cardiac risk factors.  
On examination her heart rhythm varied between atrial fibrillation with ventricular 
rate of approximately 120 bpm, and atrial flutter with a 2:1 block. Blood pressure was 
110/70 mmHg, JVP was elevated 4 cm with V waves, and clinically the pulmonary 
component of her second heart sound was loud. She had a diffuse goitre 
approximately 120 g with no bruit. FT4 was 57 pmol/L and FT3 more than 46 
pmol/L. She reverted to sinus rhythm following a single dose of intravenous 
metoprolol, and was commenced on carbimazole 40 mg mane, prednisone 50 mg 
mane and atenolol.  
Echocardiography showed normal left ventricular size and function (EF 60–65%), 
moderately dilated right ventricular size with normal function, severe mitral and 
tricuspid regurgitation with normal valve structure, and moderate pulmonary 
hypertension with RVSP 57 mmHg. Next echo done 4 weeks later revealed preserved 
left ventricular systolic function of 65%, right ventricular systolic pressure (RVSP) 
improved to 48 mmHg with moderate tricuspid and mitral regurgitation. She was 
clinically and biochemically euthyroid. 
Asymptomatic pulmonary hypertension on echocardiography is common in 
individuals with hyperthyroidism. Siu et al found 47% of individuals with 
hyperthyroidism had pulmonary arterial systolic pressures greater than 35 mmHg, and 
Suk et al reported a prevalence of pulmonary hypertension of 44% in untreated 
Graves disease patients.1,2 The pulmonary hypertension resolved upon achieving an 
euthyroid state. 
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Symptomatic thyrocardiac involvement requiring hospital admission however is 
uncommon, and these three cases of women of Māori ethnicity who have presented in 
the last 6 years represent at least one-third of patients who have required hospital 
admission for management of symptomatic thyrocardiac disease at our hospital in the 
last decade. 
The prevalence of overt hyperthyroidism in 2 general practices in Hamilton, New 
Zealand was found to be 0.2%, with no statistical difference between the Māori and 
New Zealand European population after adjustment for age and gender. According to 
2006 Census data, individuals identifying as being of Māori ethnicity represent only 
0.007% of the population in Brisbane.  
Our experience raises the question as to whether symptomatic cardiac involvement is 
more common in women of Māori ethnicity with Graves disease. This would seem 
more likely to be due to a genetic susceptibility, rather than the severity of 
thyrotoxicosis due to medication non-adherence.  
Our cases did have some family history of thyroid disorders, but no significant family 
history of thyrocardiac disease, that we could identify. Interestingly, we have also 
cared for a gentleman of Māori ethnicity who developed thyrotoxic periodic paralysis.  
A previous study found a 37-fold over-representation for Polynesians (Māori and 
Pacific Islander) compared with New Zealand Europeans for thyrotoxic periodic 
paralysis.4 This raises the possibility that individuals of Polynesian ethnicity are at 
increased risk for both cardiac and skeletal muscle complications of thyrotoxicosis. 
It is possible our experience is due to chance. We feel, however, the possible 
association between Māori ethnicity and cardiac involvement with thyrotoxicosis 
warrants further examination, particularly given the implications for Māori women of 
childbearing age, and the adverse outcomes that may be associated with pulmonary 
hypertension and cardiac disease in pregnancy. 
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